Welcome to our dedicated page for Clover Health Investments SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clover Health Investments, Corp. (Nasdaq: CLOV) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a publicly traded Medicare Advantage and healthcare technology issuer. Clover Health files reports with the U.S. Securities and Exchange Commission that describe its Medicare Advantage insurance operations, technology platform, financial performance, risk factors, and governance.
Investors can review current reports on Form 8-K, where Clover Health announces material events such as quarterly financial results, CMS Star Ratings for its Medicare Advantage PPO and HMO plans, and board or governance changes. Some 8-K filings also reference supplemental written responses to shareholder questions, offering additional context on strategy, cohort economics, and the role of Clover Assistant and Counterpart Health in the business.
In addition to 8-Ks, Clover Health’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the feed) typically provide detailed discussions of its Insurance segment, Medicare Advantage membership trends, non-GAAP measures such as Adjusted EBITDA and Insurance Benefits Expense Ratio, and regulatory considerations related to Medicare, CMS Star Ratings, and value-based care arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand how items such as Star Rating changes, CMS rate updates, or shifts in membership mix may affect Clover Health’s reported results. Users can also track insider transaction reports on Form 4 when they appear, to monitor equity transactions by directors and officers.
Filings are updated in near real time from the SEC’s EDGAR system, allowing investors, analysts, and other stakeholders to follow Clover Health’s evolving disclosures on Medicare Advantage performance, technology initiatives through Clover Assistant and Counterpart Health, and corporate governance developments.
Clover Health Investments executive Jamie L. Reynoso, CEO, Medicare Advantage, sold 5,833 shares of Class A common stock in an open-market transaction at a weighted average price of $1.91 per share. The shares were sold in multiple trades between $1.87 and $1.96 per share pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025. After this sale, Reynoso directly holds 2,716,735 Class A shares.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting the proposed sale of 5,833 Restricted Stock Units on 03/14/2026. The filing also discloses prior 10b5-1 sales by Jamie Reynoso: 4,597 shares on 01/20/2026 and 2,102 shares on 01/07/2026, with reported dollar amounts of 11,871.75 and 5,319.32, respectively.
Clover Health Investments executive Jamie L. Reynoso reported automatic share withholdings to cover tax obligations tied to restricted stock units that vested on March 14 and 15, 2026. On March 14, 6,945 shares of Class A Common Stock were withheld at $1.98 per share, followed by 6,187 shares on March 15 at the same price. These are coded as tax-withholding dispositions rather than open-market sales. After the March 15 withholding, Reynoso directly holds 2,722,568 Class A shares.
The March 14 withholding relates to the final 6.25% vesting of time-based RSUs granted on March 14, 2022. The March 15 withholding relates to 6.25% of RSUs granted on September 16, 2022, which continue to vest quarterly in 6.25% installments through a final vesting date on September 15, 2026, subject to Reynoso’s continued service.
Clover Health Investments reported a routine tax-related share withholding by its General Counsel and Secretary, Karen Soares. On March 15, 2026, 4,528 shares of Class A common stock were automatically withheld to cover taxes when 6.25% of her September 15, 2022 time-based RSU grant vested. The remaining RSUs vest quarterly in 6.25% installments through September 15, 2026, subject to her continued service. After this withholding, she directly held 1,200,061 shares of Class A common stock.
Clover Health Investments, Corp. insider Conrad Wai, CEO of Counterpart Health, reported a routine tax-related share withholding. On March 14, 2026, 100,195 shares of Class A Common Stock were automatically withheld to cover tax obligations when the final 6.25% of his time-based RSUs granted on March 14, 2022 vested.
Following this tax-withholding disposition, Wai directly holds 925,611 shares of Class A Common Stock. He also has an indirect position of 1,610,482 shares held in a trust for his family's benefit, where he serves as co-trustee. The filing reflects compensation-related mechanics rather than an open-market sale.
Clover Health Investments, Corp. filed an amended report furnishing a supplemental shareholder Q&A that expands on its fourth quarter 2025 earnings communication. Management emphasizes that its 2026 guidance is anchored on achieving positive full-year GAAP net income, positioning this as proof of structural earnings power in its Medicare Advantage model.
The Q&A explains that strong member retention, a 4-Star payment year in 2026, cohort maturation, and deeper use of the Clover Assistant technology are expected to support improving unit economics. Clover describes its approach as focused on disciplined underwriting, operating leverage and medical cost performance rather than relying on favorable reimbursement changes.
The company also discusses pausing most broker commissions from January 1, 2026 outside selected New Jersey plans to prioritize onboarding quality and provider integration, outlines a strategy to improve Star Ratings, and highlights Counterpart Health as an asset-light, technology-driven platform built on Clover Assistant to help external partners manage risk and care more effectively over time.
Clover Health Investments, Corp. furnished an update to investors by publishing written responses to a selection of frequently asked supplemental questions related to its fourth quarter 2025 earnings announcement. The company aims to further engage its shareholder base through this additional Q&A material.
The supplemental shareholder questions and answers are included as Exhibit 99.1 to this report and are also available in the investor relations section of the company’s website. This information is furnished under Regulation FD and is not deemed filed for liability purposes under the Exchange Act.
Clover Health Investments executive Brady Patrick Priest, CEO of Home Care, reported an open-market sale of Class A Common Stock. On March 4, 2026, he sold 175,000 shares at a weighted average price of $2.17 per share, in multiple trades between $2.16 and $2.18.
After this transaction, Priest held 1,998,584 shares of Clover Health Class A Common Stock in direct ownership.
CLOV reported a proposed sale of 175000 common shares under a Form 144. The filing lists a broker-dealer Morgan Stanley Smith Barney LLC Executive Financial Services and shows transaction details dated 03/04/2026.
The filing also itemizes restricted stock lots with grant/vesting dates: 57,627 (10/18/2025), 69,009 (01/18/2026) and 48,364 (10/15/2025).
Clover Health Investments, Corp. files its annual report describing a technology-focused Medicare Advantage business that remains unprofitable while pursuing growth. The company reported net losses of $85.5 million in 2025, $46.3 million in 2024, and $210.1 million in 2023, resulting in an accumulated deficit of roughly $2.3 billion as of December 31 2025.
Clover’s strategy centers on its Clover Assistant software, which uses data and machine learning to support physicians in managing chronic disease earlier and lowering medical costs. The platform underpins its Medicare Advantage plans and a newer external SaaS and tech-enabled services offering, Counterpart Health, aimed at other payors and providers.
The report highlights heavy dependence on Medicare Advantage premiums, intense competition from large insurers and health-tech players, and extensive regulatory oversight. Management flags risks from ongoing net losses, potential capital needs, cybersecurity and privacy requirements, government payment and audit processes, and the concentration of voting power in Class B shareholders.